TheraCoat, Ltd., a Raanana, Israel-based clinical stage specialty pharmaceutical company focused on innovative drug-delivery solutions for the treatment of intra-cavital diseases, completed a $7m funding round.
Backers included Pontifax, and Chaim Hurvitz’s CHealth Fund. In conjunction with the funding, Mr. Hurvitz and Ran Nussbaum, a manager partner at Pontifax, joined the company’s board, chaired by Professor. Arie Belldegrun MD FACS.
The company intends to use the funds to advance clinical trials in a number of urologic applications and start the marketing process with its lead product, which recently received CE approval for marketing in Europe.
founded in 2004 and led by Gil Hakim, CEO, TheraCoat developed an innovative platform technology to improve drug delivery into internal cavities.
The company currently focuses on three bladder indications – non-muscle invasive bladder and Urothelial cancer (NMIBC & UTUC) and overactive bladder (OAB).